- Home
- GOSS vs OCGN Comparison
GOSS vs OCGN Comparison
Compare GOSS & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- OCGN
- Stock Information
- Founded
- GOSS 2015
- OCGN 2013
- Country
- GOSS United States
- OCGN United States
- Employees
- GOSS N/A
- OCGN N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOSS Health Care
- OCGN Health Care
- Exchange
- GOSS Nasdaq
- OCGN Nasdaq
- Market Cap
- GOSS 262.5M
- OCGN 278.3M
- IPO Year
- GOSS 2019
- OCGN N/A
- Fundamental
- Price
- GOSS $1.23
- OCGN $1.03
- Analyst Decision
- GOSS Strong Buy
- OCGN Strong Buy
- Analyst Count
- GOSS 4
- OCGN 3
- Target Price
- GOSS $7.75
- OCGN $6.00
- AVG Volume (30 Days)
- GOSS 2.6M
- OCGN 8.5M
- Earning Date
- GOSS 08-11-2025
- OCGN 08-07-2025
- Dividend Yield
- GOSS N/A
- OCGN N/A
- EPS Growth
- GOSS N/A
- OCGN N/A
- EPS
- GOSS N/A
- OCGN N/A
- Revenue
- GOSS $124,590,000.00
- OCGN $4,522,000.00
- Revenue This Year
- GOSS N/A
- OCGN N/A
- Revenue Next Year
- GOSS $91.14
- OCGN N/A
- P/E Ratio
- GOSS N/A
- OCGN N/A
- Revenue Growth
- GOSS N/A
- OCGN N/A
- 52 Week Low
- GOSS $0.66
- OCGN $0.52
- 52 Week High
- GOSS $1.55
- OCGN $1.98
- Technical
- Relative Strength Index (RSI)
- GOSS 54.09
- OCGN 55.00
- Support Level
- GOSS $1.25
- OCGN $0.95
- Resistance Level
- GOSS $1.44
- OCGN $1.15
- Average True Range (ATR)
- GOSS 0.10
- OCGN 0.11
- MACD
- GOSS -0.00
- OCGN -0.02
- Stochastic Oscillator
- GOSS 41.67
- OCGN 22.62
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").